Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Recommendation of “Hold” from Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have been assigned an average recommendation of “Hold” from the ten research firms that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $8.4286.

A number of research analysts recently issued reports on IOVA shares. UBS Group boosted their price objective on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research report on Thursday, March 5th. Barclays boosted their price objective on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Wall Street Zen upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Chardan Capital reduced their price target on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Monday, April 6th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Arcataur Capital Management LLC acquired a new position in Iovance Biotherapeutics during the 4th quarter worth $29,000. Granite Investment Partners LLC acquired a new position in Iovance Biotherapeutics during the 4th quarter worth $29,000. Motley Fool Asset Management LLC bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth $29,000. M&T Bank Corp bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth $31,000. Finally, SBI Securities Co. Ltd. raised its stake in shares of Iovance Biotherapeutics by 169.1% in the 4th quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock worth $32,000 after buying an additional 7,269 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA opened at $3.93 on Thursday. Iovance Biotherapeutics has a 12-month low of $1.66 and a 12-month high of $5.63. The firm has a market capitalization of $1.75 billion, a P/E ratio of -4.14 and a beta of 0.74. The business has a 50 day simple moving average of $3.77 and a 200 day simple moving average of $3.27.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19). Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The business had revenue of $71.43 million during the quarter, compared to analyst estimates of $77.84 million. During the same quarter in the previous year, the firm posted ($0.36) EPS. The business’s revenue for the quarter was up 44.9% compared to the same quarter last year. Research analysts anticipate that Iovance Biotherapeutics will post -0.63 EPS for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.